How long should you be on Wegovy, and what happens when you stop?

Step 1: The titration phase (roughly the first five months)

Treatment begins at 0.25 mg once weekly, a starter dose whose job is to let your body adjust, not to produce immediate weight loss. The schedule moves through 0.5 mg, 1.0 mg and 1.7 mg at roughly monthly intervals, reaching the standard maintenance dose of 2.4 mg at around week 17. The newer 7.2 mg single-dose pen, approved by the MHRA in April 2026, sits beyond that for eligible adults, with the same gradual titration ladder leading up to it.

This phase matters more than people realise. A question our prescribers hear most weeks is whether the first few pens are "working" because appetite suppression is mild early on. That's expected. Progress during titration is about tolerance; the meaningful weight-loss data comes later.

Your prescriber sets the pace. If side effects are significant at any step, they may hold the dose for an extra four weeks rather than push ahead. That's clinically appropriate and has no bearing on your eventual outcome. You can read more about how the medicine behaves in these early weeks on our guide to when Wegovy starts working.

Step 2: The active treatment phase and the six-month checkpoint

Once you reach your maintenance dose, you're in the phase where the trial evidence was gathered. The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults without diabetes over 68 weeks and found an average weight reduction of around 15% at 2.4 mg, alongside lifestyle support.

Six months at maintenance is a meaningful milestone. NICE TA875 states that if you haven't lost at least 5% of your starting body weight by that point, continuing is unlikely to be the right call. This isn't a failure threshold; it's a safeguard that ensures treatment is working hard enough to justify the clinical risk and cost. If you are responding well, treatment continues with regular review.

For NHS patients, NICE recommends semaglutide only within a specialist weight management service, for a maximum of two years. Private prescribing follows the licensed indication rather than this specific two-year cap, but responsible prescribers still apply the same logic: ongoing treatment requires ongoing evidence of benefit.

Step 3: The stopping decision and what the evidence says about weight regain

Stopping Wegovy isn't like finishing a course of antibiotics. The appetite-regulating effects are active only while the medicine is present; once you stop, hunger signals typically return to their pre-treatment levels within weeks. Clinical trial data from the STEP 1 extension study showed that participants who discontinued semaglutide regained most of the weight they had lost within a year, on average.

That doesn't mean stopping is always wrong. Some people use Wegovy to reach a weight at which lifestyle changes become sustainable independently. Others find that the metabolic picture has improved enough (blood pressure, glucose, sleep) to make the case for stopping with a plan. The honest framing, supported by NHS England's guidance on weight management injections, is that weight management medicines work while you take them, and stopping should be a deliberate clinical decision, not something that happens when supply runs out or cost becomes a barrier.

If you're comparing duration considerations across GLP-1 medicines, our page on how long to be on semaglutide covers the broader licensed context. And for a sense of what private treatment costs over a realistic treatment horizon, the Wegovy cost page sets out what's included in a private prescription.

Step 4: Ongoing review and long-term planning

The most useful thing to take from the evidence is that duration should be intentional. At each repeat (whether on the NHS or through a private pharmacy) your prescriber should be asking: is this still working? Are the benefits still outweighing the risks? Is there a plan for the longer term? Our guides on how long you should use Wegovy and how long you should stay on Wegovy explore these questions in more depth, covering both the clinical evidence and the practical factors that shape individual decisions.

Obesity is a chronic condition shaped by biology, not habit. A medicine that reduces weight sustainably over one or two years is doing real clinical work, and the question of how long to stay on it deserves the same seriousness as duration decisions for any other long-term medicine. That means weight monitoring, a look at any side effects, and a realistic conversation about what stopping would mean for you specifically.

For more detail on the licensed indication and what the full treatment picture looks like, our Wegovy overview is a good starting point. If you'd like to explore whether treatment is right for you, check your eligibility with our prescribers, there's no charge for the consultation.